<DOC>
	<DOCNO>NCT02063594</DOCNO>
	<brief_summary>This randomize , double-blind , single dose , dose-escalation study evaluate safety , tolerability , pharmacokinetics NCTX ( PEGylated Liposomal Iodixanol Injection ) administer intravenously healthy volunteer . In addition , compute tomography ( CT ) scan acquired measure radiographic density region interest ( ROI ) time 3-5 hour 72 hour follow NCTX administration .</brief_summary>
	<brief_title>Single Dose Safety , Tolerability Pharmacokinetic Study NCTX Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy , nonsmoking men woman 18 55 year age Body Mass Index ( BMI ) 18.5 30.0 kg/m2 Serum creatinine within normal range calculate creatinine clearance 80 mL/min/1.73 m2 great Concurrent enrollment another clinical trial treatment investigational product therapy within 30 day prior dose History infusion reaction liposome , nanoparticles , monoclonal antibody , intravenously administer material History allergic/anaphylactoidlike reaction attribute iodinated contrast agent component formulation Disturbances normal fat metabolism , total cholesterol great 240 mg/dL Pregnant nursing woman Exposure significant radiation within 1 year , previous CT scan within 5 year prior checkin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Iodixanol</keyword>
	<keyword>Iodinated Contrast</keyword>
	<keyword>Liposome</keyword>
	<keyword>Computed Tomography</keyword>
	<keyword>X-ray Imaging</keyword>
	<keyword>Blood pool agent</keyword>
	<keyword>Biomarker</keyword>
</DOC>